NCT02077660

Brief Summary

The purpose of this study is to evaluate the beneficial effects of a long term (12 weeks) green tea drinking on plasma, erythrocytes and saliva oxidative stress biomarkers and antioxidant capacity, as well as on cardiometabolic risk factors: anthropometric, inflammation and metabolic parameters in a healthy aging men and women.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
43

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2011

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2011

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2014

Completed
11 days until next milestone

First Submitted

Initial submission to the registry

February 12, 2014

Completed
20 days until next milestone

First Posted

Study publicly available on registry

March 4, 2014

Completed
Last Updated

March 12, 2014

Status Verified

March 1, 2014

Enrollment Period

2.3 years

First QC Date

February 12, 2014

Last Update Submit

March 11, 2014

Conditions

Keywords

Green tea, aging, oxidation, anthropometrics.

Outcome Measures

Primary Outcomes (7)

  • Plasma protein carbonyls

    Protein carbonyls, nmol/mg

    24 weeks

  • Plasma thiobarbituric acid reactive substance

    Thiobarbituric acid reactive substance , nmol/mL

    24 weeks

  • Plasma lipid peroxides

    Lipid peroxides, nmol/mL

    24 weeks

  • Erythrocytes catalase

    Catalase activity, milliunits/mg

    24 weeks

  • Erythrocytes resistance to oxidative hemolysis

    hemolysis test, percentage

    24 weeks

  • Saliva enzymatic antioxidants

    Oral peroxidase activity, milliunits/mg

    24 weeks

  • Saliva antioxidant capacity

    Total antioxidant capacity, millimolar/mg

    24 weeks

Secondary Outcomes (6)

  • Total body weight

    24 weeks

  • Total body fat percentage

    24 weeks

  • Body circumference

    24 weeks

  • Serum inflammatory status

    24 weeks

  • Saliva inflammatory status Saliva matrix metalloproteinase 8 (MMP8)

    24 weeks

  • +1 more secondary outcomes

Study Arms (2)

4 daily placebo tea bags for 12 weeks

PLACEBO COMPARATOR

All subjects will undergo a 12 weeks supplemented with four daily placebo maltodextrin "tea-bags". The subjects will be instructed than to brew the placebo sachets for five minute in 240 mL boiling water without stirring and to drink 4 cups per day for 12 weeks period (Placebo period).

Other: 4 daily placebo tea bags for 12 weeks

Four green tea bags per day for 12 weeks

EXPERIMENTAL

After the placebo period, all subjects will undergo a 12 weeks supplemented with four daily green tea bags. The subjects will be instructed than to brew the green tea sachets for five minute in 240 mL boiling water without stirring and to drink 4 cups per day for 12 weeks period (Green tea period).

Dietary Supplement: Four green tea bags per day for 12 weeks

Interventions

Four green tea bags per day for 12 weeks

Four green tea bags per day for 12 weeks

4 daily placebo tea bags for 12 weeks

4 daily placebo tea bags for 12 weeks

Eligibility Criteria

Age60 Years - 76 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy men and women
  • Age: 60-76 Years
  • Able to understand the meaning of Informed Consent procedure and willing to consent

You may not qualify if:

  • Any active disease state
  • Unstable chronic disease (diabetes, vascular, renal)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rambam MC

Haifa, Israel

Location

Study Officials

  • Yishai Levy, Professor

    Rambam Health Care Campus

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 12, 2014

First Posted

March 4, 2014

Study Start

November 1, 2011

Primary Completion

February 1, 2014

Study Completion

February 1, 2014

Last Updated

March 12, 2014

Record last verified: 2014-03

Locations